Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy
…, SK Tyring, M Stuschke, M Roggendorf… - The Lancet infectious …, 2002 - thelancet.com
Kaposi's sarcoma (KS) is a mesenchymal tumour involving blood and lymphatic vessels.
Only recently has the pathogenesis of this extraordinary neoplasm been elucidated. Viral …
Only recently has the pathogenesis of this extraordinary neoplasm been elucidated. Viral …
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma
…, SK Tyring, M Stuschke, M Roggendorf… - The Lancet infectious …, 2002 - thelancet.com
The pathogenesis of Kaposi's sarcoma (KS) is better understood since the identification of
the novel human herpesvirus 8 (HHV8), which can be found in all forms of KS. Viral …
the novel human herpesvirus 8 (HHV8), which can be found in all forms of KS. Viral …
Cardio-oncology-strategies for management of cancer-therapy related cardiovascular disease
Current therapy of advanced cancers is based on several modalities including radiotherapy,
cytotoxic chemotherapy, molecularly targeted inhibitors and antibodies targeting immune …
cytotoxic chemotherapy, molecularly targeted inhibitors and antibodies targeting immune …
[PDF][PDF] Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
M Stahl, M Stuschke, N Lehmann, HJ Meyer… - Journal of clinical …, 2005 - llusurgonc.org
… Stuschke (radiation oncology), FW Eigler … Okawa T, Dokiya T, Nishio M, et al: Multiinstitutional
randomized trial of external radiotherapy with and without intraluminal brachytherapy for …
randomized trial of external radiotherapy with and without intraluminal brachytherapy for …
[PDF][PDF] Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the …
M Stahl, MK Walz, M Stuschke, N Lehmann, HJ Meyer… - J clin oncol, 2009 - academia.edu
… Hansjochen Wilke Manuscript writing: Michael Stahl, Martin Stuschke, Nils Lehmann,
Hansjochen Wilke … Siewert JR, Stein HJ, Feith M, et al: Histologic tumor type is an …
Hansjochen Wilke … Siewert JR, Stein HJ, Feith M, et al: Histologic tumor type is an …
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers …
…, M Bolla, J Bernier, A Lusinchi, M Stuschke… - Radiotherapy and …, 1997 - Elsevier
Background and purpose: A 5 week-hyperfractionated and accelerated radiotherapy regimen
without reduction of the total dose was developed to fight tumour repopulation during …
without reduction of the total dose was developed to fight tumour repopulation during …
German S3-guideline" Diagnosis and treatment of esophagogastric cancer"
…, M Stahl, H Stein, C Stoll, M Stuschke… - Zeitschrift fur …, 2011 - elibrary.ru
MOEHLER M.* 1, AL-BATRAN SE, ANDUS T., ANTHUBER M., ARENDS J., ARNOLD D.,
AUST D., BAIER P., BARETTON G., BERNHARDT J., BOEING H., BÖHLE E., BOKEMEYER C., …
AUST D., BAIER P., BARETTON G., BERNHARDT J., BOEING H., BÖHLE E., BOKEMEYER C., …
Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally …
…, H Wilke, G Stamatis, M Stuschke… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE To evaluate the feasibility and efficacy of an intensive multimodality approach
with combination chemotherapy, hyperfractionated accelerated chemoradiotherapy, and …
with combination chemotherapy, hyperfractionated accelerated chemoradiotherapy, and …
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation …
…, M Stuschke, W Budach, M Baumann… - Journal of clinical …, 2005 - ascopubs.org
… by 1.4 Gy bid to a total of 70.6 Gy concurrently with FU (600 mg/m 2 , 120 hours continuous
infusion) days 1 through 5 and MMC (10 mg/m 2 ) on days 5 and 36 (C-HART) or 14 Gy (2 Gy …
infusion) days 1 through 5 and MMC (10 mg/m 2 ) on days 5 and 36 (C-HART) or 14 Gy (2 Gy …
[PDF][PDF] Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA (N2) and selected IIIB non–small-cell lung …
…, KH Jöckel, G Stamatis, M Stuschke - Journal of Clinical …, 2015 - researchgate.net
Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA (N2)
non–smallcell lung cancer. Our previous phase II study had shown the efficacy of …
non–smallcell lung cancer. Our previous phase II study had shown the efficacy of …